A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus

References

• Loke AY, Kwan ML, Wong YT, Wong AKY. The uptake of human papillomavirus vaccination and its associated factors among adolescents: a systematic review. J Prim Care Commun Health. 2017;8(4):349–62. doi:10.1177/2150131917742299.
   PubMed Web of Science ®Google Scholar
• Lacombe-Duncan A, Newman PA, Baiden P. Human papillomavirus vaccine acceptability and decision-making among adolescent boys and parents: a meta-ethnography of qualitative studies. Vaccine. 2018;36(19):2545–58. doi:10.1016/j.vaccine.2018.02.079.
   PubMed Web of Science ®Google Scholar
• Bloem P, Ogbuanu I. Vaccination to prevent human papillomavirus infections: from promise to practice. PLoS Med. 2017;14(6):e1002325. doi:10.1371/journal.pmed.1002230.
   PubMed Web of Science ®Google Scholar
• Toft L, Storgaard M, Muller M, Sehr P, Bonde J, Tolstrup M, Ostergaard L, Sogaard OS. Comparison of the immunogenicity and reactogenicity of cervarix and gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis. 2014;209(8):1165–73. doi:10.1093/infdis/jit657.
   PubMed Web of Science ®Google Scholar
• Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23. doi:10.1002/rmv.1822.
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. International agency for research on cancer multicenter cervical cancer study, G., Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27. doi:10.1056/NEJMoa021641.
   PubMed Web of Science ®Google Scholar
• Cancer IAFRO Global cancer observatory. [accessed 2019 Jul 19]. https://gco.iarc.fr/.
   Google Scholar
• Fontes A, Andreoli MA, Villa LL, Assone T, Gaester K, Fonseca LAM, Duarte AJ, Casseb J. High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in Sao Paulo, Brazil. Papillomavirus Res. 2016;2:17–20. doi:10.1016/j.pvr.2016.01.001.
   PubMed Web of Science ®Google Scholar
• de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2017;47:2–13. doi:10.1016/j.bpobgyn.2017.08.015.
   PubMed Web of Science ®Google Scholar
• Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119–27. doi:10.1016/j.virusres.2016.12.017.
   PubMed Web of Science ®Google Scholar
• Bhatia N, Lynde C, Vender R, Bourcier M. Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus. J Cutan Med Surg. 2013;17:S47–54.
   PubMed Web of Science ®Google Scholar
• Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67. doi:10.1016/S0140-6736(07)61050-2.
   PubMed Web of Science ®Google Scholar
• Giacomet V, Penagini F, Trabattoni D, Vigano A, Rainone V, Bernazzani G, Bonardi CM, Clerici M, Bedogni G, Zuccotti GV. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine. 2014;32(43):5657–61. doi:10.1016/j.vaccine.2014.08.011.
   PubMed Web of Science ®Google Scholar
• Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4(1):52–56. doi:10.1097/COH.0b013e32831a7246.
   PubMed Web of Science ®Google Scholar
• Toft L, Tolstrup M, Storgaard M, Ostergaard L, Sogaard OS. Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. Sex Health. 2014;11(6):511–23. doi:10.1071/SH14015.
   PubMed Web of Science ®Google Scholar
• Perlman S, Wamai RG, Bain PA, Welty T, Welty E, Ogembo JG. Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: a systematic review. PLoS One. 2014;9(3):e90912. doi:10.1371/journal.pone.0090912.
   PubMed Web of Science ®Google Scholar
• Dlamini SK, Madhi SA, Muloiwa R, von Gottberg A, Moosa M-YS, Meiring ST, Wiysonge CS, Hefer E, Mulaudzi MB, Nuttall J. Guidelines for the vaccination of HIV-infected adolescents and adults in South Africa. South Afr J HIV Med. 2018;19(1):1–8. doi:10.4102/sajhivmed.v19i1.839.
   Google Scholar
• Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018;5:46–58. doi:10.1016/j.pvr.2017.12.006.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757–65. doi:10.1016/S0140-6736(04)17398-4.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr., Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23. doi:10.1056/NEJMoa1405044.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–78. doi:10.1016/S1470-2045(05)70101-7.
   PubMed Web of Science ®Google Scholar
• McClymont E, Lee M, Raboud J, Coutlée F, Walmsley S, Lipsky N, Loutfy M, Trottier S, Smaill F, Klein M. The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus. Clin Infect Dis. 2019;68(5):788–94. doi:10.1093/cid/ciy575.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069.
   PubMed Web of Science ®Google Scholar
• Mavundza EMP, Wiyeh A, Wiysonge C A systematic review of the immunogenicity and safety of human papillomavirus vaccines in people living with HIV. [accessed 2019 May 09]. http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018109898.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. (updated March 2011).
   Google Scholar
• Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–06. doi:10.1016/j.jclinepi.2010.07.015.
   PubMed Web of Science ®Google Scholar
• Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Herve C, Descamps D. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31(48):5745–53. doi:10.1016/j.vaccine.2013.09.032.
   PubMed Web of Science ®Google Scholar
• Denny LA, Hendricks B, Gordon C, Hezareh M, Dobbelaere K, David MP, Thomas F. Safety and immunogenicity of the bi-valent vaccine in HIV-positive women in South Africa. Int J Gynecol Cancer. 2012;22:E590.
   Google Scholar
• Denny L, Hendricks B, Gordon C, Hervé C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Struyf F. Safety and immunogenicity of the HPV-16/18 as04-adjuvanted vaccine in HIV-positive women in South Africa up to 12 months after vaccination. Int J Gynecol Obstet. 2012;119:S323–S324. doi:10.1016/S0020-7292(12)60610-9.
   Google Scholar
• Hidalgo-Tenorio C, Ramirez-Taboada J, Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, Lopez-Ruz M, Pasquau J. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). AIDS Res Ther. 2017;14:34. doi:10.1186/s12981-017-0160-0.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA 3rd, Bryan J, Levin MJ. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis. 2012;206(8):1309–18. doi:10.1093/infdis/jis489.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Huang S, Moscicki AB, Saah A, Levin MJ. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS. 2018;32(7):851–60. doi:10.1097/QAD.0000000000001773.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010;55(2):197–204. doi:10.1097/QAI.0b013e3181de8d26.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Huang S, Moscicki AB, Song LY, Read JS, Meyer WA, Saah AJ, Richardson K, Weinberg A. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: effect of a fourth dose of vaccine. Vaccine. 2017;35(13):1712–20. doi:10.1016/j.vaccine.2017.02.021.
   PubMed Web of Science ®Google Scholar
• Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Østergaard L, Søgaard OS. Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Hum Vaccines Immunother. 2014;10(5):1147–54. doi:10.4161/hv.27925.
   PubMed Web of Science ®Google Scholar
• Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, Østergaard L, Søgaard OS. Immunogenicity and reactogenicity of cervarix ® versus gardasil® in HIV-infected adults: an RCT. Top Antivir Med. 2014;22:174–75.
   Google Scholar
• Faust H, Toft L, Sehr P, Muller M, Bonde J, Forslund O, Ostergaard L, Tolstrup M, Dillner J. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559–65. doi:10.1016/j.vaccine.2016.02.019.
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, Chen H, Cespedes MS, Leon-Cruz JT, Godfrey C, Chiao EY, Bastow B, Webster-Cyriaque J, Feng Q, Dragavon J, et al. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS clinical trials group protocol A5298. Clin Infect Dis. 2018;67(9):1339–46. doi:10.1093/cid/ciy274.
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, Chen H, Cespedes M, Paczuski P, Godfrey C, Chiao E, Luque A, Webster-Cyriaque JY, Bastow B, Cranston R. ACTG A5298: a phase 3 trial of the quadrivalent hpv vaccine in older HIV+ adults. Top Antivir Med. 2016;24:65–66.
   Google Scholar
• Cranston RD, Cespedes MS, Paczuski P, Yang M, Coombs RW, Dragavon J, Saah A, Godfrey C, Webster-Cyriaque JY, Chiao EY, et al. High baseline anal human papillomavirus and abnormal anal cytology in a phase 3 trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected individuals older than 26 years: ACTG 5298. Sex Transm Dis. 2018;45(4):266–71. doi:10.1097/OLQ.0000000000000745.
   PubMed Web of Science ®Google Scholar
• Cranston R, Yang M, Paczuski P, Cespedes M, Chiao E, Webster-Cyriaque J, Godfrey C, Wilkin T. Baseline data of a phase 3 trial of the quadrivalent hpv vaccine in HIV+ males and females: ACTG 5298. Top Antivir Med. 2014;22:364.
   Google Scholar
• Zurek Munk-Madsen M, Toft L, Kube T, Richter R, Ostergaard L, Søgaard OS, Tolstrup M, Kaufmann AM. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. Hum Vaccin Immunother. 2018;14(4):909–16. doi:10.1080/21645515.2017.1407896.
   PubMed Web of Science ®Google Scholar
• Anderson JS, Hoy J, Hillman R, Barnden M, Eu B, McKenzie A, Gittleson C. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr. 2009;52(3):371–81. doi:10.1097/QAI.0b013e3181b7354c.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57(5):735–44. doi:10.1093/cid/cit319.
   PubMed Web of Science ®Google Scholar
• Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014;59(1):127–35. doi:10.1093/cid/ciu238.
   PubMed Web of Science ®Google Scholar
• Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, Loutfy M, Trottier S, Smaill F, Yudin MH, et al. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine. 2016;34(40):4799–806. doi:10.1016/j.vaccine.2016.08.016.
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS. 2006;20(8):1151–55. doi:10.1097/01.aids.0000226955.02719.26.
   PubMed Web of Science ®Google Scholar
• Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246–53. doi:10.1086/656320.
   PubMed Web of Science ®Google Scholar
• Response C Randomized controlled trials of human papillomavirus vaccines: systematic reviews. [accessed 2019 May 09]. https://www.who.int/immunization/sage/meetings/2016/october/04_Clinical_trials_of_HPV_vaccines.pdf.
   Google Scholar
• Mugo NR, Eckert L, Magaret AS, Cheng A, Mwaniki L, Ngure K, Celum C, Baeten JM, Galloway DA, Wamalwa D, et al. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: month 7 and 12 post vaccine immunogenicity and correlation with immune status. Vaccine. 2018;36(46):7025–32. doi:10.1016/j.vaccine.2018.09.059.
   PubMed Web of Science ®Google Scholar